<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552953</url>
  </required_header>
  <id_info>
    <org_study_id>CYC065-01</org_study_id>
    <nct_id>NCT02552953</nct_id>
  </id_info>
  <brief_title>A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers</brief_title>
  <official_title>A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclacel Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyclacel Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single arm, dose escalation study in patients with advanced cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single arm, dose escalation study in patients with advanced cancers.
      Treatment will be administered on an outpatient basis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who experience dose-limiting toxicities</measure>
    <time_frame>cycle 1(each cycle is 21 -28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations</measure>
    <time_frame>cycle 1(each cycle is 21 -28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of CYC065</measure>
    <time_frame>cycle 1(each cycle is 21 -28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in certain protein levels in peripheral white blood cells by western blots</measure>
    <time_frame>cycle 1(each cycle is 21 -28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>CYC065 - 4 hour infusion (Part 1 completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYC065 will be administered by 4 -hour infusion every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYC065 - 1 hour infusion (Part 2 - ongoing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYC065 will be administered by 1 - hour infusion on Days 1, 2, 8, and 9 every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYC065 - Oral (Part 3 - ongoing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYC065 will be administered orally on Days 1, 2, 8 and 9 every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYC065</intervention_name>
    <arm_group_label>CYC065 - 1 hour infusion (Part 2 - ongoing)</arm_group_label>
    <arm_group_label>CYC065 - 4 hour infusion (Part 1 completed)</arm_group_label>
    <arm_group_label>CYC065 - Oral (Part 3 - ongoing)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed solid tumors or lymphomas that is metastatic
             or unresectable and for which standard curative or palliative measures do not exist or
             are no longer effective

          -  18 years or older

          -  ECOG performance status 0-1

          -  Life expectancy â‰¥ 3 months

          -  Evaluable disease

          -  Adequate organ functions

          -  4 weeks from prior chemotherapy ( 6 weeks for mitomycin C and nitrosourea) ,
             immunotherapy, investigational anti-cancer therapy, radiation therapy; and have
             recovered from prior toxicities

          -  At least 4 weeks from major surgery

          -  Agree to practice effective contraception

          -  Agree to follow protocol required evaluations

          -  Ability to understand and willingness to sign the informed consent form

        Exclusion Criteria:

          -  Previously untreated CNS metastasis or progressive CNS metastasis

          -  Currently receiving radiotherapy, biological therapy, or any other investigational
             agents

          -  Uncontrolled intercurrent illness

          -  Pregnant or lactating women

          -  Known to be HIV-positive

          -  Known active hepatitis B and/or hepatitis C infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Shapiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judy Chiao, MD</last_name>
    <phone>908-517-7330</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Shapiro, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Andrew Wolanski, NP</last_name>
      <phone>617.632.6623</phone>
      <email>Andrew_wolanski@dfci.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

